Donate For Public and Patients Store Search

S011 - Inflammatory Skin Diseases: The Translational Revolution

Friday, March 1; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Determine what are the mechanisms that underlie the major inflammatory skin diseases (psoriasis, atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa, acne and rosecea)
  • Utilize the understanding of mechanisms of disease to evaluate the novel therapeutics
  • Assess differences and similarities between inflammatory skin diseases and how these relate to novel treatments

Description

In the past decade we experienced a revolution in the mechanistic understanding of inflammatory skin diseases. This translational revolution started with psoriasis, and is now extending to many other common inflammatory skin diseases, and particularly atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa, acne and rosacea. These advances translate to rapid development and testing in early and late stage clinical trials of more narrow, targeted treatments for these diseases, that are safer for long-term disease control. In this symposium we will address both the increased understanding and the novel therapeutic developments for several inflammatory skin diseases, to ultimately improve patient care.

Disclosures

  • Bissonnette, Robert, MD, MSc: AbbVie – I(Grants/Research Funding); Bausch Health – C(H); BMS – A(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Boston Pharmaceuticals – C(H); Dermavant Sciences – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), I(Grants/Research Funding); Escalier – I(Grants/Research Funding); Janssen-Ortho Inc. – C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – C(H), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding);
  • Christiano, Angela, PhD: Aclaris Therapeutics Inc. – C(Fees); Dermira – C(H); Pfizer Inc. – I(Grants/Research Funding);
  • Guttman, Emma, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Almirall – A(H), C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Asana Biosciences, LLC – A(H), C(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), C(H), I(Grants/Research Funding); Cara Therapeutics – A(H), C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Concert Pharmaceuticals – C(H), I(Grants/Research Funding); DBV Technologies – A(H), C(H); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), C(H), I(Grants/Research Funding); DS Biopharma – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding); EMD Serono – C(H); Escalier – A(H), C(H); FLX Bio – C(H); Galderma Research & Development, LLC – A(H), C(H), I(Grants/Research Funding); Glenmark Generics Inc. – A(H), C(H), I(Grants/Research Funding); Incyte Corporation – A(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – A(H), C(H), I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novan – A(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H), I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Sanofi – A(H), C(H); Sienna Biopharmaceuticals – A(H), C(H), I(Grants/Research Funding); UCB – I(Grants/Research Funding); Union Therapeutics – C(H), I(Grants/Research Funding);
  • Harris, John, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); BiologicsMD, Inc. – C(H); Celgene Corporation – I(Grants/Research Funding); Combe Incorporated – C(Fees); Concert Pharmaceuticals – A(H); Dermavant Sciences – C(Fees), I(Grants/Research Funding); Dermira – I(Grants/Research Funding); EMD Serono – C(H); Genzyme Corporation – C(H), I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – C(H); Leo Pharma Inc – I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novartis – C(Fees); Pfizer Inc. – C(H), I(Grants/Research Funding); Rheos Medicines – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); TeVido Biodevices, LLC – A(SO), I(Grants/Research Funding), SH(ST); Third Rock Ventures – A(H); Villaris Therapeutics, Inc – F(ST), I(Grants/Research Funding);
  • Krueger, James G., MD, PhD: AbbVie – C(H); Akros Pharma, Inc. – I(Grants/Research Funding); Allergan, Inc. – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Arena Pharmaceuticals – C(H); Aristea – C(H); Asana Biosciences, LLC – C(H); Aurigene Discovery Technologies, Inc. – C(H); Avillion – I(Grants/Research Funding); Biogen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Botanix Pharmaceuticals – I(Grants/Research Funding); Bristol-Myers Squibb – C(H), I(Grants/Research Funding); Celgene – C(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), I(Grants/Research Funding); Escalier – C(H); Exicure – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); Leo Pharma Inc. – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Nimbus Therapeutics – C(H); Novan – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Parexel – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Sanofi US Services – C(H); Sienna Biopharmaceuticals – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H); Vitae Pharmaceuticals – I(Grants/Research Funding);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Avotres, Inc. – C(H); BirchBioMed – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Cara Therapeutics – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dermavant Sciences – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Inozyme Pharma – C(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
Schedule
Friday, March 1
1:00 PM
Dr. Guttman and Dr. Krueger / Introduction
1:05 PM
Dr. Lebwohl / The Last Decade in Inflammatory Skin Diseases
1:25 PM
Dr. Krueger / Pathogenic and Therapeutic Advances in Psoriasis
1:50 PM
Dr. Guttman / The Translational Revolution in Atopic Dermatitis
2:15 PM
Dr. Harris / New Developments in Vitiligo
2:40 PM
Dr. Bissonnette / New advances in Hidradenitis Suppurativa, Acne and Rosacea
3:05 PM
Dr. Christiano / Advances in Alopecia Areata
3:30 PM
Dr. Krueger / Summary and future directions
3:35 PM
All faculty / Q & A
Event Details
  • Date
    Friday, March 1
  • Time
    1:00 PM - 4:00 PM
  • Location
    Ballroom B
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Emma Guttman, MD, PhD, FAAD - Handout
  • James G. Krueger, MD, PhD, FAAD - Handout
Speakers
  • Angela Christiano, PhD
  • John Harris, MD, PhD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Robert Bissonnette, MD, MSc, FAAD